Issues
-
Cover Image
Cover Image
Cancer-derived exosomes have profound and broad effects in cell culture but understanding their role in vivo has been hindered in the absence of physiologically relevant models. In this issue, Gargiulo and colleagues provide comprehensive evidence in genetic mouse models that chronic lymphocytic leukemia (CLL)-secreted exosomes in vivo are taken up by T cells and contribute to CLL progression by suppressing antitumor immunity. As the cover illustrates, they find that in absence of exosomes (left side), CD8+ T cells (white) are metabolically fit, produce cytokines, and release cytotoxic granules directly to the CLL target cells to their rapid elimination. In presence of leukemia-associated exosomes (right side), CD8+ T-cell activity is inhibited by immune checkpoint receptor engagement and transfer of proteins and microRNAs. As a result, CD8+ T cells are metabolically altered and unable to produce polyfunctional cytokines or properly release cytotoxic granules. For details, see the article on p. 54 and accompanying commentary by Zhong and Guo on p. 5. Cover image by Ella Maru Studio. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
In This Issue
In the Spotlight
Research Articles
A Therapeutically Targetable NOTCH1–SIRT1–KAT7 Axis in T-cell Leukemia
In T-ALL, a targetable SIRT1-KAT7 axis is revealed whereby NOTCH1 binding to an enhancer transcriptionally upregulates SIRT1, and SIRT1 promotes leukemia progression by deacetylating and activating KAT7.
ETV6 Deficiency Unlocks ERG-Dependent Microsatellite Enhancers to Drive Aberrant Gene Activation in B-Lymphoblastic Leukemia
An imbalance between activating and repressive ETS transcription factors transforms genomic GGAA tandem repeats into leukemia-specific enhancers that drive the unique gene expression signature of ETV6-RUNX1+ B-ALL.
Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses
Exosomes produced in the leukemia microenvironment inhibit CD8+ T cell-mediated antitumor immunity by immune checkpoint interactions and miRNA transfer sustaining CLL development in mouse models.
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies
Novel mouse models of Myd88-driven DLBCL serve as preclinical platforms to evaluate combined BTK/BCL2 inhibition and immune-therapeutic approaches.
Acknowledgment to Reviewers
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.